Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases
Ulf W. Tunn1, Amulf Stenzl2, Wolfgang Schultze-Seemann3, Arne Strauss4, Manfred Kindler5, Kurt Miller6, Manfred P. Wirth7, Niko Zantl8, Matthias Schulze9, Christoph May10, Amelie Ruebel10, Katrin Birkholz10, Viktor Gruenwald11
Canadian Journal of Urology, Vol.19, No.3, pp. 6261-6267, 2012
Abstract Introduction: Approximately 30% of patients with renal cell cancer (RCC) develop bone metastasis, causing skeletal-related events (SREs): pathologic fracture, spinal cord compression, surgery to bone, and radiotherapy. Zoledronic acid demonstrated significant clinical benefit in RCC patients in a retrospective analysis. The primary objective of this prospective study was to evaluate the proportion of patients experiencing ≥ 1 SRE during 12 months of zoledronic acid treatment and to verify the retrospective data.
Materials and methods: Fifty patients with histologically confirmed RCC and evidence of ≥ 1 cancer-related bone lesion, and ≤ 3 prior bisphosphonate applications were enrolled across… More >